Abnormal expression of CDH2 has been reported in many cancers, including that of the lung, breast, and prostate, as well as squamous cell carcinoma.7 Abnormal expression of CDH2 can regulate the progression of malignant tumors by affecting apoptosis, angiogenesis, invasion, and metastasis of tumor cells.8 Therefore, CDH2 may be used as a therapeutic target and prognostic biomarker for multiple tumors.9 Cadherin 13 (CDH13, T-cadherin, H-cadherin) is a new member of the cadherin superfamily that maintains normal tissue structure. Here, CDH13 is linked to neoplasm.